In 2005, the annual nationwide cost (in the USA) to treat hospitalized patients with methicillin-resistant Staphylococcus aureus
(MRSA) infections was estimated to be between $3.2 billion to $4.2
billion, according to a analysis presented at the annual meeting of the
International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). The high costs of treating infections caused by MRSA, a
serious, multi-drug resistant-pathogen, are primarily driven by
prolonged hospital stays, including time spent in intensive care
units.(source: http://www.infectioncontroltoday.com/hotnews/55h168584264313.html) 
Xeralife, with its patented T-Zap technology, is able fight MRSA infections. Contrary to chemical based germicides which attempt to act on the MSRA’s DNA structure, T-Zap attacks and decomposes the bacteria’s cell walls. As such, viruses and bacteria are not able to build-up resistance. Once the decomposition of the MSRA cell is complete, only carbon dioxide and water are released into the environment.
Using Xeralife products in hospitals can reduce the likelihood of cross-contamination. Through the use of Xeralife, hospitals can provide a germ-free environment, protecting doctors and patients alike.
We have conducted long term experiments in hospitals, showing the reduced risk of MRSA infections by placing a Xeralife Room Decontaminator unit in patient’s rooms. To obtain the results on this, please contact: Địa chỉ email này đã được bảo vệ từ spam bots, bạn cần kích hoạt Javascript để xem nó.
